Lercanidipin-Hcl Stada

Lercanidipine hydrochloride, the active ingredient in Lercanidipin-Hcl Stada, is a calcium channel blocker presented as a tablet for oral use. It treats hypertension in adult patients by lowering elevated blood pressure. GNH USA supplies Lercanidipin-Hcl Stada as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lercanidipine hydrochloride is used to manage hypertension, a condition characterized by chronically elevated arterial pressure.

Hypertension: reduces systolic and diastolic blood pressure, helping to lower the risk of cardiovascular events. Essential hypertension: provides long‑term blood pressure control in primary hypertension. High blood pressure: assists in achieving target blood pressure goals as part of antihypertensive therapy.

Lercanidipine hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Headache: mild to moderate intensity, often transient. - Flushing: sensation of warmth and redness, especially on the face. - Peripheral edema: swelling of ankles or lower legs. - Dizziness or light‑headedness, particularly after standing. - Tachycardia: increased heart rate in some patients. - Gastrointestinal discomfort: nausea or abdominal pain.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure causing fainting. - Myocardial infarction: rare occurrence of heart attack. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: rash, pruritus, or angioedema. - Cardiac arrhythmias: abnormal heart rhythms. - Stevens‑Johnson syndrome: rare severe skin reaction.

Before initiating therapy with lercanidipine, clinicians should consider several safety aspects.

Monitor blood pressure: adjust dose based on therapeutic response. Avoid abrupt discontinuation: taper to prevent rebound hypertension. Caution in hepatic impairment: dose may need adjustment. Use carefully in elderly patients: increased sensitivity to hypotension. Avoid concomitant strong CYP3A4 inhibitors: may raise drug levels. Store at ambient temperature: keep in original packaging, protect from moisture and direct sunlight.

Lercanidipine can interact with several medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma concentrations. - Co‑administration with other antihypertensives: risk of excessive hypotension. - Grapefruit juice: can elevate drug exposure. - Simultaneous use with diltiazem or verapamil: additive calcium‑channel blockade. - Rifampicin: may reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Diuretics: monitor electrolytes and blood pressure. - Beta‑blockers: may require dose adjustments. - NSAIDs: can attenuate antihypertensive response. - Antidiabetic agents: monitor glucose control. - Lipid‑lowering statins: observe for muscle toxicity.